Apixaban, marketed as Eliquis, faces a dynamic competitive landscape within the anticoagulant market. Its primary competitors include other direct oral anticoagulants (DOACs) and older warfarin-based therapies.
What other DOACs are competing with Eliquis?
The main DOAC competitors to apixaban are rivaroxaban (Xarelto) and dabigatran (Pradaxa) [1][2]. Edoxaban (Savaysa) is another DOAC, though it has a smaller market share [1]. These drugs offer similar mechanisms of action, primarily inhibiting specific clotting factors to prevent thrombus formation [2].
How does Eliquis compare to warfarin?
Warfarin, a vitamin K antagonist, has been the standard anticoagulant for decades but requires regular blood monitoring (INR) and dietary adjustments [3]. Apixaban, as a DOAC, generally offers a more predictable effect without routine monitoring and has fewer drug and food interactions, contributing to its widespread adoption [2][3]. However, warfarin remains a cost-effective option, particularly for certain patient populations or in regions where DOACs are less accessible [3].
When does apixaban's patent protection expire?
The patent landscape for apixaban is complex, with various patents covering its composition of matter, methods of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for predicting the entry of generic versions and understanding market exclusivity [4]. The primary composition of matter patent for apixaban is expected to expire in the coming years, opening the door for generic competition [4].
What are the risks and side effects of apixaban?
The primary risk associated with apixaban and all anticoagulants is bleeding [5]. While generally considered to have a lower risk of intracranial hemorrhage compared to warfarin in some studies, all anticoagulants carry this potential serious adverse event [5]. Other side effects can include bruising and gastrointestinal issues [5].
Who manufactures apixaban?
Apixaban is co-developed and marketed by Bristol Myers Squibb and Pfizer [1].